The Trump administration has now signed most-favored-nation pricing agreements with seventeen drug manufacturers, deals built to pull the prices those companies charge in the United States down toward the lowest amount any wealthy nation pays for the same medicine. The agreements reach two channels in particular: what state Medicaid programs pay, and what cash-paying patients are charged directly. For older Americans who rely on Medicaid or who buy medications without insurance, the arrangements aim squarely at the long-standing gap between American drug prices and the far lower figures common across other high-income countries.
What most-favored-nation pricing is meant to do
The core idea behind a most-favored-nation price is comparison. Rather than negotiating each drug in isolation, the policy ties an American price to the lowest price a manufacturer already accepts in a peer country such as Germany, Canada, or Japan, on the argument that patients in the United States should not pay several times what buyers abroad pay for an identical product. The manufacturers entered the framework voluntarily, trading price concessions for a three-year reprieve from threatened tariffs on their products, an unusual arrangement that swaps trade leverage for pricing commitments rather than relying on a negotiating statute.
The approach is distinct from the separate Medicare drug-price negotiations already underway under earlier law. Those negotiations let Medicare bargain directly over a defined list of high-spending drugs for people with Part D, and they proceed on their own statutory track with binding, published prices. The most-favored-nation deals are a parallel, executive-branch effort that leans on trade pressure instead, which is part of why they land on Medicaid and cash buyers rather than inside the Medicare benefit that most retirees actually use.
That trade is the mechanism that brought seventeen separate companies to the table. In announcing the seventeenth deal, reached with the drugmaker Regeneron, the White House described a framework that gives every state Medicaid program access to most-favored-nation prices on the company’s products. Each of the seventeen agreements follows a similar shape, extending MFN pricing into Medicaid and committing the manufacturers to sell drugs directly to consumers who pay cash.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
Where the seventeen deals actually reach
The savings are concentrated where the government or the patient pays directly, not across the whole market at once. The administration’s own analysis projects that requiring manufacturers to extend most-favored-nation prices to state Medicaid programs would generate tens of billions of dollars in combined federal and state savings over a decade, money that flows through the programs covering low-income and dual-eligible older Americans. Medicaid is the clearest beneficiary because the government negotiates on behalf of millions of enrollees at a single stroke.
The cash channel is the second target. The deals commit manufacturers to sell selected drugs to self-paying patients at reduced prices, generally routed through a federal direct-to-consumer portal that links out to each company’s own site. That structure matters for retirees who fall into coverage gaps, pay out of pocket for a drug their plan excludes, or carry no drug coverage at all, since the cash price is precisely what those buyers confront at the counter with nothing to offset it. For a retiree rationing a medication because insurance will not cover it, a lower direct price can be the difference between filling a prescription and skipping it, which is where the deals could matter most in practice.
What the deals leave untouched
The reach of the agreements stops well short of the entire pharmacy. According to a trade publication tracking every signed agreement, the deals center on Medicaid and cash pricing and do not directly rewrite what private insurance or Medicare Part D plans pay, which is where most older Americans actually fill their prescriptions. A retiree with a standard Part D plan may see little change at the register even as Medicaid and cash prices move, because the negotiated discounts do not automatically pass into commercial or Medicare formularies.
The terms also carry limits that blunt the headline figure. The concessions run for three years and the precise contract details are largely confidential, so the size of any individual price cut is hard to verify from the outside. Health-policy analysts have cautioned that some cash prices offered through the new channel can still exceed what a generic version or an insured copay would cost, meaning the lowest advertised number is not always the cheapest route for a given patient.
Independent reviews of the early results have been mixed. Analysts examining the first wave of agreements found that while some targeted prices fell, other list prices in the same companies’ portfolios rose over the same stretch, so the net effect on what Americans pay is harder to read than the announcements imply. That unevenness is why the practical value of any single deal turns on the specific drug a person needs rather than on the headline pledge to bring most-favored-nation pricing to American patients.
For older buyers, the practical question is which channel they actually use. A dual-eligible retiree whose drugs run through Medicaid stands to gain the most, a cash payer buying a specific brand through the direct portal may capture a real discount, and a typical Part D enrollee sits largely outside the deals’ direct reach. The value of seventeen signatures, in other words, depends entirely on where a given person’s prescriptions are paid for.
The larger unknown is durability. Because the agreements are voluntary, three years in length, and anchored to a tariff threat rather than a statute, their staying power beyond the current administration is untested. Whether most-favored-nation pricing eventually widens from Medicaid and cash into the coverage most retirees carry remains the open question that will decide how much these deals matter for the average older household.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
